Lifeboat Foundation

https://www.youtube.com/watch?v=9MdsF3P8bjw

I was in a really interesting 1-hour debate yesterday with Jean-Francois Gariépy who runs a well-known YouTube channel The Public Space, sometimes associated with the Alt-Right. We discussed #transhumanism. I think the debate caught a lot of people by surprise. While I believe in and embrace total diversity, I despise the oppression of human biology and death, and advocate for any means possible to overcome it—including genetic modification and merging with machines. The debate makes me look like the aggressor. But it only proves what I’ve always said, that issues of race and traditional cultural bigotry are minor compared to the issues of humanity battling aging and death itself. All of us are currently in a war to not die:

An important debate on whether or not humanity should play with their own genes. Guest: Zoltan Istvan, transhumanist.

Continue reading “Should We Replace Ourselves? | Zoltan Istvan vs. JFG, TPS #257” »

Ok, the new version of my global risk prevention map is up (pdf link is in comments) and now it is accompanied by recently the published article “Approaches to the Prevention of Global Catastrophic Risks.”

Abstract: Many global catastrophic and existential risks (X-risks) threaten the existence of humankind. There are also many ideas for their prevention, but the meta-problem is that these ideas are not structured. This lack of structure means it is not easy to choose the right plan(s) or to implement them in the correct order. I suggest using a “Plan A, Plan B” model, which has shown its effectiveness in planning actions in unpredictable environments. In this approach, Plan B is a backup option, implemented if Plan A fails. In the case of global risks, Plan A is intended to prevent a catastrophe and Plan B to survive it, if it is not avoided. Each plan has similar stages: analysis, planning, funding, low-level realization and high-level realization. Two variables—plans and stages—provide an effective basis for classification of all possible X-risks prevention methods in the form of a two-dimensional map, allowing the choice of optimal paths for human survival. I have created a framework for estimating the utility of various prevention methods based on their probability of success, the chances that they will be realized in time, their opportunity cost, and their risk. I also distinguish between top-down and bottom-up approaches.

New program coming on-line at Bioquark Inc. (www.bioquark.com) — Ectocrine interactions (the“Ectocrinome”) represents a completely unexplored area related to human health

https://www.prweb.com/releases/bioquark_inc_and_ectocrine_te…004155.htm

Long live these genes!

Happy holidays! The winter break is here, and LEAF too will shift to a lower gear for a little while, but on the plus side, our readers get the Rejuvenation Roundup early! Before we leave you to unwrapping presents and having dinner with the family, let’s recap what has been going on in the field of rejuvenation during the last month of the year.

Had a great time with my regenerative biology Q&A session with Ayersville (Ohio, USA) Schools 2nd graders and high school advanced anatomy class — so happy to see kids out there that are interested in these topics at such a young age — creating the future, one mind at a time — https://www.youtube.com/watch?v=2_uu9f7nafc

I am overjoyed to be co-hosting the second “Undoing Aging” conference together with Michael Greve just one year after the first, thanks to the generosity and hard work of Michael’s Forever Healthy Foundation and their team.

It is now entirely appropriate to be holding conferences on rejuvenation biotechnology every year, given how rapidly the field and the industry have grown relative to a decade ago, when my conferences in Cambridge were biannual. As you will see below, we are again assembling a huge variety of world-leading speakers whose research spans all aspects of rejuvenation biotechnology.

During the Fourth Eurosymposium on Healthy Ageing (EHA), which was held in Brussels, Belgium last November, we had the opportunity to meet Dr. Daniel Muñoz-Espín from the Oncology Department of the University of Cambridge.

Dr. Muñoz-Espín received his PhD from the Autonomous University of Madrid, Spain, within the viral DNA replication group at the Centre of Molecular Biology Severo Ochoa, where he worked under the supervision of one of the most famous Spanish scientists, Dr. Margarita Salas. Dr. Muñoz-Espín’s postdoctoral research resulted in several published papers and a 2013 patent focused on DNA replication; he then joined the Centro Nacional de Investigaciones Oncológicas, or CNIO, the Spanish National Centre for Cancer Research, specifically the team of Dr. Manuel Serrano, co-author of The Hallmarks of Aging. The research that Dr. Muñoz-Espín conducted during this time demonstrated how cellular senescence doesn’t play a role just in aging and cancer but also in normal embryonic development, where it contributes to the shaping of our bodies—a process that was termed “developmentally-programmed senescence”, whose concept was very favorably received by the scientific community.

Currently, Dr. Muñoz-Espín serves as Principal Investigator of the Cancer Early Detection Programme at the Department of Oncology of Cambridge University; with his current team, Dr. Muñoz-Espín developed a novel method to target senescent cells, which was reported in EMBO Molecular Medicine. This topic was the subject of Dr. Muñoz-Espín’s talk at EHA2018 and one of the many fascinating others that he discussed in this interview.

The topic for the December Journal Club will be the recently published paper – Fisetin is a senotherapeutic that extends health and lifespan. This commonly available supplement and a plant-based polyphenol appears to influence the aging process in mice by clearing senescent cells, one of the suggested reasons we age.

If you like watching these streams and/or would like to participate in future streams, please consider supporting us by becoming a Lifespan Hero: https://www.lifespan.io/hero

Paper: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6197652/